To disseminate and promote leading scientific advances and knowledge in diabetes research, treatment, education, and advocacy, the International Diabetes Federation (IDF) will host the IDF Virtual Congress 2023 from December 4 to 7, focusing on diabetes-related complications. During the conference, more than 130 international experts will discuss the latest research, treatments and tools to manage, treat and prevent diabetes complications¹.

The IDF Virtual Congress 2023 will featurethree dedicated streams offering the latest scientific advances in the management and prevention of diabetes complications affecting the cardiovascular system, eyes, kidneys, feet and nerves. A fourth stream will focus on the impact of natural and man-made disasters on people living with diabetes and the long-term effects of Covid-19. All four streams will include the experiences of people living with diabetes, which play a key role in understanding, managing and preventing diabetes complications¹. Additionally, the conference will introduce the latest epidemiological and impact data on diabetes complications fromthe IDF Diabetes Altason the opening day, the 4th of December.

During the four-day high-level conference, the results of Gan & Lee Pharmaceuticals' independently developed insulin aspart 70/30 (Rapilin^®️30) Phase III clinical study in China will be presented in an e-Poster format in the virtual conference's e-Poster Gallery, giving attendees ample opportunity to learn about the clinical research achievements of Rapilin^®️30 through IDF's virtual platform.

Gan & Lee Pharmaceuticals Insulin Aspart 30 (Rapilin^®️ 30)

Efficacy and safety of GL insulin aspart 70/30 compared with reference insulin in Chinese patients with DM

Venue：e-Poster Gallery

Abstract Number：IDF23-0286

Presentation Type：e-Poster

Principal Investigator: Wenying Yang丨 China-Japan Friendship Hospital, China

Presenter: Xin Wang丨China-Japan Friendship Hospital, China

IDF Virtual Congress 2023 Venue²

Rapilin^®️30 Phase III Clinical Study

The Phase III clinical study of Gan & Lee insulin aspart 70/30 (Rapilin^®️30) in China aims to demonstrate the similar efficacy and safety of Gan & Lee Pharmaceuticals' Rapilin^®️30 in patients with Type 1 and Type 2 diabetes compared to the reference product NovoRapid^®️30. The study, using a randomized, open-label, parallel-controlled trial design, involved 569 patients with Type 1 and Type 2 diabetes, exploring the bioequivalence in efficacy and safety of Rapilin^®️30 compared to NovoRapid^®️30 after 24 weeks of continuous administration.

International Diabetes Federation (IDF)

The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950.

The IDF Congress is one of the largest health conferences globally, aimed at disseminating and promoting leading scientific advances and knowledge in diabetes research, treatment, education, and advocacy. The detailed schedule of IDF 2023 is now available on the official website. For more information, please visit IDF Virtual Congress 2023 official website: https://idf2023.org/  

References：

1.     WELCOME MESSAGE FROM THE PROGRAMME CHAIR. IDF Virtual Congress 2023. https://idf2023.org/welcome/ 

2.     【IDF Virtual Congress 2023】Focusing on Diabetes Complications. IDF WeChat Platform. https://mp.weixin.qq.com/s/HK8L0IHL8M1_8OBsUZUh7Q

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.